Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Carboplatin (Primary) ; Dupilumab (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 17 Oct 2024 New trial record